Celecoxib attenuates hepatosteatosis by impairing de novo lipogenesis via Akt‐dependent lipogenic pathway

Mounting evidence indicates that hepatic de novo lipogenesis is a common abnormality in non‐alcoholic fatty liver disease (NAFLD) patients. We investigated whether a selective COX‐2 inhibitor, celecoxib, alleviates hepatic steatosis by targeting an Akt‐driven lipogenic pathway. We estimated the effi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Cong, Lu, Yuzhen, Song, Yingying, Chen, Liang, Hu, Junjie, Meng, Yan, Chen, Xin, Li, Shan, Zheng, Guohua, Qiu, Zhenpeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279593/
https://www.ncbi.nlm.nih.gov/pubmed/35713152
http://dx.doi.org/10.1111/jcmm.17435

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279593/
https://www.ncbi.nlm.nih.gov/pubmed/35713152
http://dx.doi.org/10.1111/jcmm.17435

Ejemplares similares